Ultra-rapid lispro or fast-acting aspart compared to standard insulin lispro and aspart using closed-loop insulin therapy: a systematic review and meta-analysis of randomized control trials.

Front Endocrinol (Lausanne) · 2025 · PMC12178897 · PMID 40547532

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

borderline significantP=0.06so close (0.05 < p ≤ 0.1)

In insulin subgroup analyses, Fiasp showed a borderline significant increase in TIR (70-180 mg/dl) [MD 1.20%, 95% CI (-0.04, 2.43), P=0.06, I2=0%], while URLi demonstrated no significant effect [MD -0.19%, 95% CI (-2.43, 2.05), P=0.87, I2=20%]; the difference between these two insulins was also not significant ( Supplementary Figure 37 ).

also in 3,616 other papers

near-significantP = 0.06so close (0.05 < p ≤ 0.1)

On the other hand, Insulin Delivery Systems: Perspectives, Ideas, Reflections, and Expectations [INSPIRE score] showed a near-significant increase among ultra-rapid insulin users [MD 3.98, 95% CI [-0.24 to 8.2], P = 0.06, I 2 = 20] ( Supplementary Figure 35b ). 3.6.

also in 1,099 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.